Literature DB >> 32226615

Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.

Laura A Huppert1, John D Gordan1, Robin Kate Kelley2.   

Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-reading-huppert a video presentation of this article Answer questions and earn https://www.wileyhealthlearning.com/Activity/7036144/disclaimerspopup.aspx.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32226615      PMCID： PMC7098670          DOI： 10.1002/cld.879

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  10 in total

Review 1.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

2.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

Review 3.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

Authors:  Alan P Venook; Christos Papandreou; Junji Furuse; Laura Ladrón de Guevara
Journal:  Oncologist       Date:  2010

Review 4.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Authors:  Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

10.  Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.

Authors:  Dimitri Gassmann; Stefan Weiler; Joachim C Mertens; Cäcilia S Reiner; Bart Vrugt; Mirjam Nägeli; Joanna Mangana; Beat Müllhaupt; Fabienne Jenni; Benjamin Misselwitz
Journal:  Transplant Direct       Date:  2018-07-20
  10 in total
  11 in total

1.  Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals.

Authors:  Federica Vernuccio; Roberto Cannella; Giuseppe Cabibbo; Silvia Greco; Ciro Celsa; Francesco Matteini; Paolo Giuffrida; Massimo Midiri; Vito Di Marco; Calogero Cammà; Giuseppe Brancatelli
Journal:  Diagnostics (Basel)       Date:  2022-05-10

2.  TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.

Authors:  Yuchuan Jiang; Siliang Chen; Qiang Li; Junjie Liang; Weida Lin; Jinying Li; Zhilong Liu; Mingbo Wen; Mingrong Cao; Jian Hong
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

3.  Probing Synergistic Targets by Natural Compounds for Hepatocellular Carcinoma.

Authors:  Jian Gao; Zuojing Yin; Zhuanbin Wu; Zhen Sheng; Chao Ma; Rui Chen; Xiongwen Zhang; Kailin Tang; Jian Fei; Zhiwei Cao
Journal:  Front Cell Dev Biol       Date:  2021-07-28

4.  Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report.

Authors:  Yu-Min Feng; Tsung-Hsien Chen; Dara Berman; Chu-Kuang Chou; Kai-Sheng Liao; Ming-Chih Hsieh; Chi-Yi Chen
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

Review 5.  Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.

Authors:  Burcin Özdirik; Fabian Jost-Brinkmann; Lynn Jeanette Savic; Raphael Mohr; Frank Tacke; Christoph J Ploner; Christoph Roderburg; Tobias Müller
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

6.  Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.

Authors:  Daniel Wai-Hung Ho; Yu-Man Tsui; Lo-Kong Chan; Karen Man-Fong Sze; Xin Zhang; Jacinth Wing-Sum Cheu; Yung-Tuen Chiu; Joyce Man-Fong Lee; Albert Chi-Yan Chan; Elaine Tin-Yan Cheung; Derek Tsz-Wai Yau; Nam-Hung Chia; Irene Lai-Oi Lo; Pak-Chung Sham; Tan-To Cheung; Carmen Chak-Lui Wong; Irene Oi-Lin Ng
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

Review 7.  Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.

Authors:  Yun Hua Lee; David Tai; Connie Yip; Su Pin Choo; Valerie Chew
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

Review 8.  Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

Review 9.  The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies.

Authors:  Anastasios D Giannou; Samuel Huber; Jöran Lücke; Morsal Sabihi; Tao Zhang; Lennart Fynn Bauditz; Ahmad Mustafa Shiri
Journal:  Semin Immunopathol       Date:  2021-04-13       Impact factor: 9.623

Review 10.  Immunotherapies for hepatocellular carcinoma.

Authors:  Justin K H Liu; Andrew F Irvine; Rebecca L Jones; Adel Samson
Journal:  Cancer Med       Date:  2021-12-24       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.